⌘K

Login Start Free

Home/Filings/4/0001209191-19-061048

4//SEC Filing

Mahatme Sandesh 4

Accession 0001209191-19-061048

CIK 0000873303other

View on SEC.gov Company Profile

Filed

Dec 16, 7:00 PM ET

Accepted

Dec 17, 8:00 PM ET

Size

28.5 KB

Accession

0001209191-19-061048

Insider Transaction Report

Form 4

Period: 2019-12-13

Sarepta Therapeutics, Inc.SRPT

Mahatme Sandesh

Senior Vice President, CFO

Transactions

Exercise/Conversion
Common Stock
2019-12-13$13.71/sh+4,319$59,213→ 34,498 total
Exercise/Conversion
Common Stock
2019-12-13$13.71/sh+4,138$56,732→ 38,636 total
Sale
Common Stock
2019-12-13$125.50/sh−125,000$15,687,500→ 30,179 total
Exercise/Conversion
Stock option (right to buy)
2019-12-13−4,138→ 2,633 total
Exercise: $13.71From: 2016-09-09Exp: 2026-02-28→ Common Stock (4,138 underlying)
Exercise/Conversion
Common Stock
2019-12-13$29.03/sh+69,479$2,016,975→ 118,581 total
Exercise/Conversion
Stock option (right to buy)
2019-12-13−69,479→ 0 total
Exercise: $29.03From: 2015-02-28Exp: 2024-02-28→ Common Stock (69,479 underlying)
Exercise/Conversion
Stock option (right to buy)
2019-12-13−14,723→ 39,277 total
Exercise: $34.92From: 2014-06-04Exp: 2023-06-04→ Common Stock (14,723 underlying)
Exercise/Conversion
Common Stock
2019-12-13$23.85/sh+10,466$249,614→ 49,102 total
Exercise/Conversion
Common Stock
2019-12-13$32.63/sh+21,875$713,781→ 140,456 total
Exercise/Conversion
Common Stock
2019-12-13$34.92/sh+14,723$514,127→ 155,179 total
Exercise/Conversion
Stock option (right to buy)
2019-12-13−4,319→ 3,085 total
Exercise: $13.71From: 2017-02-28Exp: 2026-02-28→ Common Stock (4,319 underlying)
Exercise/Conversion
Stock option (right to buy)
2019-12-13−10,466→ 0 total
Exercise: $23.85From: 2013-11-05Exp: 2022-11-05→ Common Stock (10,466 underlying)
Exercise/Conversion
Stock option (right to buy)
2019-12-13−21,875→ 10,874 total
Exercise: $32.63From: 2018-03-10Exp: 2027-03-10→ Common Stock (21,875 underlying)

Holdings

Common Stock
(indirect: By Trust)
12,012

Footnotes (1)

[F1]This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction.

Documents

1 file

4
doc4.xmlPrimary
FORM 4 SUBMISSION

Issuer

Sarepta Therapeutics, Inc.

CIK 0000873303

Entity typeother

Related Parties

1

filerCIK 0001511034

Filing Metadata

Form type: 4
Filed: Dec 16, 7:00 PM ET
Accepted: Dec 17, 8:00 PM ET
Size: 28.5 KB

View on SEC.gov